Full Press Release Details
MARLBOROUGH, Mass. , Feb. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an operational 1 basis and 7.0 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP earnings of $386 million or $0.27 per share (EPS), compared to a GAAP loss of $615 million or $(0.45) per share a year ago and achieved adjusted earnings per share of $0.39 for the period, compared to $0.34 a year ago.
For the full year 2018, the company generated sales of $9.823 billion . This represents growth of 8.6 percent on a reported basis, 8.0 percent on an operational basis and 7.2 percent on an organic basis, all compared to the prior year period. The company reported GAAP earnings of $1.19 per share, compared to $0.08 in the prior year period and delivered full year adjusted earnings per share of $1.47 , compared to $1.26 in 2017. Full year 2018 adjusted earnings per share includes a $0.07 net tax benefit. 3
"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said Mike Mahoney , chairman and chief executive officer, Boston Scientific. "We remain driven by the opportunity to help more patients with our life-changing technologies, including a robust long-term pipeline of new devices and therapies."
Fourth quarter financial results and recent developments:
| 1. | Operational revenue growth excludes the impact of foreign currency fluctuations. |
| 2. | Organic revenue growth excludes the impact of foreign currency fluctuations and sales from the recent acquisitions of Symetis SA, NxThera, Inc., Claret Medical, Inc. and Augmenix, Inc., each with no prior year comparable sales. |
| 3. | The full year 2018 net tax benefit of $0.07 includes our previously disclosed second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our previously announced tax reinvestment strategy. In addition, the net benefit includes a $0.06 benefit in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years. |
| 4. | The fourth quarter net tax benefit of $0.01 includes the aforementioned fourth quarter $0.05 charge for our previously announced tax reinvestment strategy, which was estimated to be $0.06 at the time of guidance issued October 24, 2018, offset by a $0.06 benefit for the aforementioned fourth quarter tax settlement. |
| 5. | We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets. |
| 6. | The LOTUS Edge Aortic Valve System is an investigational device in the United States and not available for sale. |
Net sales for the fourth quarter by business and region:
| Change | |||||||||||||||||
| Three Months Ended December 31, | Reported Basis | Less: Impact of Foreign Currency Fluctuations | Operational Basis | Less: Impact of Recent Acquisitions | Organic Basis | ||||||||||||
| (in millions) | 2018 | 2017 | |||||||||||||||
| Endoscopy | $ | 458 | $ | 436 | 5.0% | (1.6)% | 6.6% | —% | 6.6% | ||||||||
| Urology and Pelvic Health | 342 | 308 | 10.8% | (1.3)% | 12.1% | 6.5% | 5.6% | ||||||||||
| MedSurg* | 800 | 745 | 7.4% | (1.5)% | 8.9% | 2.7% | 6.2% | ||||||||||
| Cardiac Rhythm Management | 488 | 488 | 0.1% | (1.6)% | 1.7% | —% | 1.7% | ||||||||||
| Electrophysiology | 81 | 77 | 6.3% | (1.7)% | 8.0% | —% | 8.0% | ||||||||||
| Neuromodulation | 220 | 186 | 17.9% | (1.0)% | 18.9% | —% | 18.9% | ||||||||||
| Rhythm and Neuro* | 790 | 751 | 5.1% | (1.5)% | 6.6% | —% | 6.6% | ||||||||||
| Interventional Cardiology | 668 | 636 | 5.0% | (2.5)% | 7.5% | 1.4% | 6.1% | ||||||||||
| Peripheral Interventions | 302 | 277 | 9.2% | (2.0)% | 11.2% | —% | 11.2% | ||||||||||
| Cardiovascular | 970 | 913 | 6.3% | (2.3)% | 8.6% | 0.9% | 7.7% | ||||||||||
| Net Sales | $ | 2,561 | $ | 2,408 | 6.3% | (1.9)% | 8.2% | 1.2% | 7.0% |
| Change | |||||||||||||
| Three Months Ended December 31, | Reported Basis | Less: Impact of Foreign Currency Fluctuations | Operational Basis | ||||||||||
| (in millions) | 2018 | 2017 | |||||||||||
| U.S. | $ | 1,459 | $ | 1,364 | 7.0% | —% | 7.0% | ||||||
| EMEA** | 557 | 529 | 5.1% | (4.1)% | 9.2% | ||||||||
| APAC** | 445 | 423 | 5.2% | (1.9)% | 7.1% | ||||||||
| Latin America and Canada | 101 | 94 | 7.2% | (15.0)% | 22.2% | ||||||||
| Net Sales | $ | 2,561 | $ | 2,408 | 6.3% | (1.9)% | 8.2% | ||||||
| Emerging Markets | $ | 278 | $ | 238 | 16.8% | (10.4)% | 27.2% |
Net sales for the full year by business and region:
| Change | |||||||||||||||||
| Year Ended December 31, | Reported Basis | Less: Impact of Foreign Currency Fluctuations | Operational Basis | Less: Impact of Recent Acquisitions | Organic Basis | ||||||||||||
| (in millions) | 2018 | 2017 | |||||||||||||||
| Endoscopy | $ | 1,762 | $ | 1,619 | 8.8% | 0.5% | 8.3% | —% | 8.3% | ||||||||
| Urology and Pelvic Health | 1,245 | 1,124 | 10.8% | 0.2% | 10.6% | 2.5% | 8.1% | ||||||||||
| MedSurg* | 3,007 | 2,742 | 9.7% | 0.4% | 9.3% | 1.1% | 8.2% | ||||||||||
| Cardiac Rhythm Management | 1,951 | 1,895 | 2.9% | 0.8% | 2.1% | —% | 2.1% | ||||||||||
| Electrophysiology | 311 | 278 | 12.1% | 1.2% | 10.9% | —% | 10.9% | ||||||||||
| Neuromodulation | 779 | 635 | 22.7% | 0.2% | 22.5% | —% | 22.5% | ||||||||||
| Rhythm and Neuro* | 3,041 | 2,808 | 8.3% | 0.7% | 7.6% | —% | 7.6% | ||||||||||
| Interventional Cardiology | 2,590 | 2,419 | 7.1% | 0.5% | 6.6% | 2.1% | 4.5% | ||||||||||
| Peripheral Interventions | 1,187 | 1,081 | 9.8% | 0.6% | 9.2% | —% | 9.2% | ||||||||||
| Cardiovascular | 3,777 | 3,500 | 7.9% | 0.5% | 7.4% | 1.4% | 6.0% | ||||||||||
| Net Sales | $ | 9,823 | $ | 9,048 | 8.6% | 0.6% | 8.0% | 0.8% | 7.2% |
| Change | |||||||||||||
| Year Ended December 31, | Reported Basis | Less: Impact of Foreign Currency Fluctuations | Operational Basis | ||||||||||
| (in millions) | 2018 | 2017 | |||||||||||
| U.S. | $ | 5,538 | $ | 5,162 | 7.3% | —% | 7.3% | ||||||
| EMEA** | 2,176 | 1,940 | 12.2% | 3.2% | 9.0% | ||||||||
| APAC** | 1,727 | 1,587 | 8.8% | 1.3% | 7.5% | ||||||||
| Latin America and Canada | 383 | 358 | 6.8% | (9.0)% | 15.8% | ||||||||
| Net Sales | $ | 9,823 | $ | 9,048 | 8.6% | 0.6% | 8.0% | ||||||
| Emerging Markets | $ | 1,072 | $ | 909 | 18.0% | (3.4)% | 21.4% | ||||||
| *Prior period segment amounts revised in accordance with ASC 280, Segment Reporting, to reflect the reclassification of Neuromodulation from the MedSurg segment to the Rhythm and Neuro segment, effective January 1, 2018. | |||||||||||||
| **Regional totals reflect the reclassification of Middle East and Africa from the former AMEA region to Europe, effective January 1, 2018. | |||||||||||||
| Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | |||||||||||||
| Sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of recent aforementioned acquisitions are not prepared in accordance with U.S. GAAP. |
Guidance for Full Year and First Quarter 2019
The company estimates revenue growth for the full year 2019, versus the prior year period, to be in a range of approximately 7 to 9 percent on a reported basis and a growth range of approximately 7 to 8.5 percent on an organic basis, excluding the impact of changes in foreign currency exchange rates and contribution of approximately 110 basis points from the acquisitions of NxThera, Claret and Augmenix, each with no prior year comparable sales. The company estimates income on a GAAP basis in a range of $1.13 to $1.18 per share and estimates adjusted earnings, excluding amortization expense, acquisition-related, restructuring- and restructuring-related and litigation-related net charges (credits) in a range of $1.53 to $1.58 per share.
The company estimates revenue growth for the first quarter of 2019, versus the prior year period, to be in a range of approximately 6 to 7 percent on a reported basis and a growth range of approximately 7 to 8 percent on an organic basis, excluding the impact of changes in foreign currency exchange rates and contribution of approximately 160 basis points from the acquisitions of NxThera, Claret and Augmenix, each with no prior year comparable sales. The company estimates earnings on a GAAP basis in a range of $0.32 to $0.33 per share and estimates adjusted earnings, excluding amortization expense, acquisition-related, restructuring- and restructuring-related and litigation-related net charges (credits) in a range of $0.35 to $0.36 per share.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET . The company will webcast the call to interested parties through its website: www.bostonscientific.com . Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend," "aiming" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates, GAAP earnings and adjusted earnings for the first quarter and full year 2019, our financial performance, our business plans and our positioning for revenue and earnings growth. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Note : Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Prior year balances were subject to rounding.
Use of Non-GAAP Financial Information A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
| CONTACT: | |||||
| Media: | Kate Haranis | Investors: | Susie Lisa, CFA | ||
| 508-683-6585 (office) | 508-683-5565 (office) | ||||
| Media Relations | Investor Relations | ||||
| Boston Scientific Corporation | Boston Scientific Corporation | ||||
| [email protected] | [email protected] |
| BOSTON SCIENTIFIC CORPORATION | |||||||||||||
| CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS | |||||||||||||
| (Unaudited) | |||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||
| in millions, except per share data | 2018 | 2017 | 2018 | 2017 | |||||||||
| Net sales | $ | 2,561 | $ | 2,408 | $ | 9,823 | $ | 9,048 | |||||
| Cost of products sold | 729 | 673 | 2,813 | 2,593 | |||||||||
| Gross profit | 1,832 | 1,735 | 7,011 | 6,455 | |||||||||
| Operating expenses: | |||||||||||||
| Selling, general and administrative expenses | 953 | 886 | 3,569 | 3,294 | |||||||||
| Research and development expenses | 288 | 264 | 1,113 | 997 | |||||||||
| Royalty expense | 18 | 18 | 70 | 68 | |||||||||
| Amortization expense | 162 | 142 | 599 | 565 | |||||||||
| Intangible asset impairment charges | — | — | 35 | 4 | |||||||||
| Contingent consideration expense (benefit) | (10) | (3) | (21) | (80) | |||||||||
| Restructuring charges | 16 | 21 | 36 | 37 | |||||||||
| Litigation-related charges (credits) | 85 | 89 | 103 | 285 | |||||||||
| 1,513 | 1,416 | 5,504 | 5,170 | ||||||||||
| Operating income (loss) | 319 | 319 | 1,506 | 1,285 | |||||||||
| Other income (expense): | |||||||||||||
| Interest expense | (64) | (56) | (241) | (229) | |||||||||
| Other, net | 40 | (36) | 156 | (124) | |||||||||
| Income (loss) before income taxes | 296 | 227 | 1,422 | 933 | |||||||||
| Income tax expense (benefit) | (90) | 842 | (249) | 828 | |||||||||
| Net income (loss) | $ | 386 | $ | (615) | $ | 1,671 | $ | 104 | |||||
| Net income (loss) per common share - basic | $ | 0.28 | $ | (0.45) | $ | 1.21 | $ | 0.08 | |||||
| Net income (loss) per common share - assuming dilution | $ | 0.27 | $ | (0.45) | $ | 1.19 | $ | 0.08 | |||||
| Weighted-average shares outstanding | |||||||||||||
| Basic | 1,384.2 | 1,373.3 | 1,381.0 | 1,370.1 | |||||||||
| Assuming dilution | 1,406.2 | 1,373.3 | 1,401.4 | 1,392.7 |
| BOSTON SCIENTIFIC CORPORATION | |||||||||||||||||||||||||||||
| NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS | |||||||||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||||||||
| Three Months Ended December 31, 2018 | |||||||||||||||||||||||||||||
| in millions, except per share data | Cost of Products Sold | SG&A Expenses | R&D Expenses | Operating Income (Loss) | Pre-Tax Income (Loss) | Net Income (Loss) | Impact per Share | ||||||||||||||||||||||
| GAAP net income (loss) | $ | 729 | $ | 953 | $ | 288 | $ | 319 | $ | 296 | $ | 386 | $ | 0.27 | |||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Amortization expense | — | — | — | 162 | 162 | 140 | 0.10 | ||||||||||||||||||||||
| Acquisition-related net charges (credits) | (18) | (32) | (9) | 50 | 22 | 84 | 0.06 | ||||||||||||||||||||||
| Restructuring and restructuring-related net charges (credits) | (14) | (7) | (1) | 37 | 37 | 30 | 0.02 | ||||||||||||||||||||||
| Litigation-related net charges (credits) | — | — | — | 85 | 85 | 65 | 0.05 | ||||||||||||||||||||||
| Investment impairment charges | — | — | — | — | — | (2) | 0.00 | ||||||||||||||||||||||
| Discrete tax items | — | — | — | — | (7) | (151) | (0.11) | ||||||||||||||||||||||
| Adjusted net income | $ | 697 | $ | 915 | $ | 278 | $ | 653 | $ | 596 | $ | 552 | $ | 0.39 | |||||||||||||||
| Three Months Ended December 31, 2017 | |||||||||||||||||||||||||||||
| in millions, except per share data | Cost of Products Sold | SG&A Expenses | R&D Expenses | Operating Income (Loss) | Pre-Tax Income (Loss) | Net Income (Loss) | Impact per Share | ||||||||||||||||||||||
| GAAP net income (loss) | $ | 673 | $ | 886 | $ | 264 | $ | 319 | $ | 227 | $ | (615) | $ | (0.45) | |||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Amortization expense | — | — | — | 142 | 142 | 127 | 0.09 | * | |||||||||||||||||||||
| Acquisition-related net charges (credits) | (5) | (24) | (8) | 33 | 35 | 29 | 0.02 | * | |||||||||||||||||||||
| Restructuring and restructuring-related net charges (credits) | (10) | (4) | — | 34 | 34 | 26 | 0.02 | * | |||||||||||||||||||||
| Litigation-related net charges (credits) | — | — | — | 89 | 89 | 50 | 0.04 | * | |||||||||||||||||||||
| Investment impairment charges | — | — | — | — | 3 | 2 | 0.00 | * | |||||||||||||||||||||
| Discrete tax items | — | — | — | — | — | 861 | 0.62 | * | |||||||||||||||||||||
| Adjusted net income | $ | 659 | $ | 859 | $ | 256 | $ | 617 | $ | 530 | $ | 480 | $ | 0.34 | |||||||||||||||
| *Assumes dilution of 22.1 million shares for the three months ended December 31, 2017. | |||||||||||||||||||||||||||||
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. |
| BOSTON SCIENTIFIC CORPORATION | ||||||||||||||||||||||||||||
| NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS | ||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||
| Year Ended December 31, 2018 | ||||||||||||||||||||||||||||
| in millions, except per share data | Cost of Products Sold | SG&A Expenses | R&D Expenses | Operating Income (Loss) | Pre-Tax Income (Loss) | Net Income (Loss) | Impact per Share | |||||||||||||||||||||
| GAAP net income (loss) | $ | 2,813 | $ | 3,569 | $ | 1,113 | $ | 1,506 | $ | 1,422 | $ | 1,671 | $ | 1.19 | ||||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||||||||||||||
| Amortization expense | — | — | — | 599 | 599 | 520 | 0.37 | |||||||||||||||||||||
| Intangible asset impairment charges | — | — | — | 35 | 35 | 31 | 0.02 | |||||||||||||||||||||
| Acquisition-related net charges (credits) | (41) | (84) | (60) | 164 | (46) | 5 | 0.00 | |||||||||||||||||||||
| Restructuring and restructuring-related net charges (credits) | (47) | (11) | (1) | 96 | 96 | 77 | 0.05 | |||||||||||||||||||||
| Litigation-related net charges (credits) | — | — | — | 103 | 103 | 79 | 0.06 | |||||||||||||||||||||
| Investment impairment charges | — | — | — | — | 7 | 6 | 0.00 | |||||||||||||||||||||
| Discrete tax items | — | — | — | — | (7) | (328) | (0.23) | |||||||||||||||||||||
| Adjusted net income | $ | 2,724 | $ | 3,474 | $ | 1,052 | $ | 2,503 | $ | 2,209 | $ | 2,060 | $ | 1.47 | ||||||||||||||
| Year Ended December 31, 2017 | ||||||||||||||||||||||||||||
| in millions, except per share data | Cost of Products Sold | SG&A Expenses | R&D Expenses | Operating Income (Loss) | Pre-Tax Income (Loss) | Net Income (Loss) | Impact per Share | |||||||||||||||||||||
| GAAP net income (loss) | 2,593 | 3,294 | 997 | 1,285 | 933 | $ | 104 | $ | 0.08 | |||||||||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||||||||||||||
| Amortization expense | — | — | — | 565 | 565 | 492 | 0.35 | |||||||||||||||||||||
| Intangible asset impairment charges | — | — | — | 4 | 4 | 4 | 0.00 | |||||||||||||||||||||
| Acquisition-related net charges (credits) | (22) | (58) | (23) | 23 | 34 | 9 | 0.01 | |||||||||||||||||||||
| Restructuring and restructuring-related net charges (credits) | (45) | (13) | — | 95 | 95 | 75 | 0.05 | |||||||||||||||||||||
| Litigation-related net charges (credits) | — | — | — | 285 | 285 | 172 | 0.12 | |||||||||||||||||||||
| Investment impairment charges | — | — | — | — | 56 | 36 | 0.03 | |||||||||||||||||||||
| Discrete tax items | — | — | — | — | — | 861 | 0.62 | |||||||||||||||||||||
| Adjusted net income | $ | 2,525 | $ | 3,222 | $ | 974 | $ | 2,258 | $ | 1,972 | $ | 1,752 | $ | 1.26 | ||||||||||||||
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. |
| BOSTON SCIENTIFIC CORPORATION |
| ESTIMATED REVENUE NON-GAAP GROWTH RATES AND NON-GAAP NET INCOME PER SHARE RECONCILIATIONS |
| (Unaudited) |
Q1 and Full Year 2019 Estimated Revenue Growth Rates
| Q1 2019 Estimate | Full Year 2019 Estimate | ||||||||
| (Low) | (High) | (Low) | (High) | ||||||
| Estimated GAAP sales growth | 6% | 7% | 7% | 9% | |||||
| Less: Estimated impact of foreign currency fluctuations and the aforementioned acquisitions | (1)% | (1)% | —% | 0.5% | |||||
| Estimated sales growth, organic* | 7% | 8% | 7% | 8.5% | |||||
| *Q1 2019 Estimate excludes contribution of approximately 160 basis points from the aforementioned acquisitions, each with no prior year comparable sales. Full Year 2019 Estimate excludes contribution of approximately 110 basis points from the aforementioned acquisitions, each with no prior year comparable sales. |
Q1 and Full Year 2019 Earnings per Share Guidance
| Q1 2019 Estimate | Full Year 2019 Estimate | |||||||||||||
| (Low) | (High) | (Low) | (High) | |||||||||||
| GAAP results | $ | 0.32 | $ | 0.33 | $ | 1.13 | $ | 1.18 | ||||||
| Estimated amortization expense | 0.10 | 0.10 | 0.40 | 0.40 | ||||||||||
| Estimated acquisition-related net charges (credits) | 0.02 | 0.02 | 0.05 | 0.05 | ||||||||||
| Estimated restructuring and restructuring-related net charges (credits) | 0.01 | 0.01 | 0.05 | 0.05 | ||||||||||
| Estimated litigation-related net charges (credits) | (0.10) | (0.10) | (0.10) | (0.10) | ||||||||||
| Adjusted results | $ | 0.35 | $ | 0.36 | $ | 1.53 | $ | 1.58 |
Prior Guidance Estimate - Q4 2018 Earnings per Share
| Q4 2018 Estimate | ||||||
| (Low) | (High) | |||||
| GAAP results** | $ | 0.15 | $ | 0.17 | ||
| Estimated amortization expense | 0.10 | 0.10 | ||||
| Estimated acquisition-related net charges (credits) | 0.03 | 0.03 | ||||
| Estimated restructuring and restructuring-related net charges (credits) | 0.02 | 0.02 | ||||
| Adjusted results** | $ | 0.30 | $ | 0.32 | ||
| **Q4 2018 estimated GAAP and adjusted results included $0.06 of reinvestment of the $0.06 Q2 2018 benefit from the finalization of the IRS Stipulation of Settled Issues for tax years 2001 through 2010. |
Use of Non-GAAP Financial Measures
To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts, operational net sales, which exclude the impact of foreign currency fluctuations and organic net sales, which exclude the impact of foreign currency fluctuations and the impact of recent aforementioned acquisitions. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.
To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income, including amortization expense, intangible asset impairment charges, acquisition-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment charges and certain discrete tax items. Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type that management excluded as part of these non-GAAP financial measures, since our most recent Annual Report on Form 10-K, as well as the reason for excluding each individual item. In each case, management has excluded the item for purposes of calculating the relevant non-GAAP financial measure to facilitate an evaluation of our current operating performance and a comparison to our past operating performance:
The GAAP financial measures most directly comparable to adjusted net income and adjusted net income per share are GAAP net income and GAAP net income per share.
To calculate operational net sales, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. To calculate organic net sales, we remove the impact of recent aforementioned acquisitions with no prior period related net sales from operational net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.
Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.
SOURCE Boston Scientific Corporation